

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of  
**CZEKAJ, et al.**

Examiner:

Art Unit: 1624

Application No.: **10/686,871**

Filed: **October 16, 2003**

Title: **N-Acylpyrrolidin-2-ylalkylbenzamidine  
Derivatives as Inhibitors of Factor Xa**

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. 1.56, 1.97 AND 1.98**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

- ☐ (a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. **18-1982**.

- ☒ (b) This Information Disclosure Statement is filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first.
- ☐ (1) The undersigned attorney certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement;
- ☐ (2) The undersigned attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; or
- ☒ (3) This Information Disclosure Statement is accompanied by a transmittal letter in which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is authorized.

The items listed on the attached PTO-1449 (modified) have been previously submitted by the examiner or the applicant in related applications of this series:

10/143,190 filed on May 10,2002

Therefore, a copy of the reference(s) are not enclosed with this Information Disclosure Statement.

Respectfully submitted,

/Joseph D. Rossi/

Joseph D. Rossi, Reg. No. 47,038

Attorney for Applicant

Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Telephone (908) 231-**3410**  
Telefax (908) 231-2626

Docket No. DEAV1999/S005 US CIP1



+

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				<b>Application Number</b>	10/686,871
				<b>Filing Date</b>	10-16-2003
				<b>First Named Inventor</b>	CZEKAJ
				<b>Group Art Unit</b>	1624
				<b>Examiner Name</b>	T.C. McKenzie
<b>Sheet</b>	<b>1</b>	<b>of</b>	<b>2</b>	<b>Attorney Docket Number</b>	DEAV1999/S005 - US - CIP1

[illegible][illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

+

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/686,871
				Filing Date	10-16-2003
				First Named Inventor	CZEKAJ
				Group Art Unit	1624
				Examiner Name	T.C. McKenzie
Sheet	2	of	2	Attorney Docket Number	DEAV1999/S005 - US -CIP1

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		ARISAWA, Mitsuhiro et al., Construction of Chiral 1,2-Cycloalkanopyrrolidines from L-Proline Using Ring Closing Metathesis (RCM), Chem. Pharm. Bull (2000), 48(10), 1593-1596	
		ARISAWA, Mitsuhiro et al., Synthesis of Chiral Bicyclic Lactams Using Ring-Closure Metathesis: Synthesis of (-)-Coniceine and (S)-Pyrrolam A, Synlett (1997), (10), 1179-1180	
		WOLFF, Manfred, Burger's Medicinal Chemistry and Drug Discovery, 5ed, Vol.1, John Wiley & Sons, 1995, pages 975-977.	
		BANKER, G.S., et al. et al., Modern Pharmaceutics, 3ed., Marcel Dekker, Inc., New York, 1996, page 596	
		HAN, William T. et al., Azetidin-2-One Derivatives as Inhibitors of Thrombin, Bioorganic & Medicinal Chemistry, Elsevier Scient Ltd, GB, vol. 3, no. 8, 1995, pages 1123-1143	
		HERBERT, Richard B. et al., Synthesis of (+-)-Norruspoline, J. Chem. Res., Synop. (1982), (11), p. 299	
		NEUKOMM, G. et al., Zur Struktur von Hypercratin, einem weiteren Alkaloid aus Ruspolia Hypercrateriformis Organic Natural Products. Part 188. Structure of Hypercratine, Another Alkaloid of Ruspolia Hypercrateriformis, Planta Med. (1983), Vol. 48(4), 246-52	
		OKADA, Midori et al., Fluoro-Lactonization of 4-Alkenoic Acid Derivatives with N-Fluoropentachloropyridinium Triflate, J. Fluorine Chem. (1997), 82(2), 157-161	
		ROESSLER, Felix et al., Ruspolia Hypercrateriformis M.R.: Isolation and Structure Elucidation of New Pyrrolidine Alkaloids, Helv. Chim. Acta (1978), Vol. 61, Fasc. 3, 1200-1206	
		SHAN, Daxian, et al., Prodrug Strategies Based on Intramolecular Cyclization Reactions, J. Pharmaceutical Sciences, 1997, 86, pages 765-767	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.